Biocardia (BCDA)Director bought ~$360K

~$360K

Approx. value · 288K sh @ $1.25

634K

Holds after · shares reported

Traded

Sep 19, 2025

Filed

Sep 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 11, 2025InsiderCEO purchased ~$3K of BCDA shares in the open market
2. Aug 12, 2025InsiderCEO purchased ~$700 of BCDA shares in the open market
3. Aug 13, 2025InsiderCEO purchased ~$183 of BCDA shares in the open market
4. Aug 22, 2025InsiderCEO purchased ~$1.3K of BCDA shares in the open market
5. Sep 19, 2025 · this disclosureInsider · 3 insiders in a week, 8th time since 2007Director purchased ~$360K of BCDA shares in the open market

What came next

1. Sep 19, 2025Insider · 2 peopleInsiders: 2 purchases (~$558K)
2. Sep 24, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 4, 2025 (the “Original 8-K”), on April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its…”
3. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
4. Dec 2, 2025Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote (and 1 more item)“On December 2, 2025, the Board of Directors (the “Board”) of BioCardia, Inc. (the “Company” or “BioCardia”) appointed Marvin Slosman as a member of the Board, with an initial term beginning immediately and expiring at BioCardia’s 2028 Annual Meeting of Shareholders, or until his successor is duly elected and qualified.”
5. Dec 16, 2025InsiderCEO purchased ~$274 of BCDA shares in the open market
6. Dec 17, 2025InsiderCEO purchased ~$1.2K of BCDA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Biocardia

For Biocardia, OQRO holds 9 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCDA page.

Other recent filings by Andrew Scott Blank, Director

• SEC Form 4 at Biocardia (BCDA)Jul 3, 2025
• SEC Form 4 at Biocardia (BCDA)Apr 26, 2025

The full history of Andrew Scott Blank, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Biocardia

• SEC Form 4Sep 30, 2026
• SEC Form 4Sep 24, 2026
• SEC Form 4Sep 5, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 4Aug 13, 2026
• SEC Form 4Jul 30, 2026

Everything OQRO holds on this company is on its BCDA page.